Intracranial Pressure
0 original drugs 0
Novel Drugs
16
Reformulations
0
Active Trials
0
Drug Targets
Intracranial Pressure has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Novel Intracranial Pressure Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (16 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
BRONCHITOL
PHARMAXIS EUROPE
T10 2020
ARIDOL KIT
PHARMAXIS EUROPE
T3 2010
ARIDOL
PHARMAXIS EUROPE
T3 2010
MANNITOL 20% IN PLASTIC CONTAINER
B BRAUN
T5 1987
MANNITOL 10% IN PLASTIC CONTAINER
B BRAUN
T5 1987
MANNITOL 15% IN PLASTIC CONTAINER
B BRAUN
T5 1987
MANNITOL 5% IN PLASTIC CONTAINER
B BRAUN
T5 1987
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Pfizer
T5 1976
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 20% IN WATER
Baxter
T5 1964
OSMITROL 5% IN WATER
Baxter
T5 1964
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
Baxter
T5 1964
OSMITROL 15% IN WATER
Baxter
T5 1964
OSMITROL 10% IN WATER
Baxter
T5 1964
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs